Reviewer’s report

Title: Hemodialysis Patients’ Preferences for the Management of Secondary Hyperparathyroidism

Version: 0 Date: 13 Feb 2017

Reviewer: Stuart Sprague

Reviewer's report:

Interesting analysis of patient preference of either oral, parenteral with dialysis or surgery for the treatment of SHPT in a cohort of dialysis patients which reveal that patients would prefer parenteral administration of medication.

Comments

Surprising that only 25% of subjects knew they had SHPT

Interesting that the question of having oral medications given during dialysis was not an option, as it is a common practice and patients may prefer taking a pill with dialysis as opposed to having an injection, especially since the issue of pill burden at home was identified as a negative aspect of oral medications

Not sure there is a need for both Table 1 and Fig 1

The title is rather redundant, having both Hemodialysis and ESRD describing the patient population

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I have received research funding as well as consulting fees from Amgen

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal